# Rotigotine

## Neupro patch 6mg/24h

| 藥物代碼 | ENEU |
| :--- | :--- |
| 適應症 | Parkinson's disease |
| 副作用 | \(Common\)Cardiovascular: Orthostatic hypotension \(up to 18% \), Peripheral edema \(2% to 9% \)Dermatologic: Application site reaction \(21% to 46% \), Diaphoresis \(Parkinson disease, 3% to 11%; restless leg syndrome, 1% to 5% \), Pruritus \(3% to 9% \)Endocrine metabolic: Weight increased \(2% to 9% \)Gastrointestinal: Loss of appetite \(2% to 8% \), Nausea \(Parkinson disease, 28% to 48%; restless leg syndrome, 15% to 23% \), Vomiting \(Parkinson disease, 10% to 20%; restless leg syndrome, 2% to 4% \), Xerostomia \(3% to 7% \)Musculoskeletal: Arthralgia \(11% \)Neurologic: Asthenia \(7% to 14%\), Dizziness \(Parkinson disease, 14% to 23%; restless leg syndrome, 5% to 9% \), Dysesthesia \(5% \), Dyskinesia \(7% to 14% \), Headache \(Parkinson disease, 8% to 14%; restless leg syndrome, 15% to 21% \), Insomnia \(5% to 11% \), Paresthesia \(5%\), Sleep disorder \(2% to 10% \), Somnolence \(Parkinson disease, 12% to 32%; restless leg syndrome, 5% to 10% \)\(Serious\)Cardiovascular: SyncopeNeurologic: Sleep attack \(1% to 2% \)Psychiatric: Compulsive behavior, Hallucinations \(4% to 7% \), Impulse control disorder |
| 禁忌 | Hypersensitivity to rotigotine or any component of the product. |
| 藥物保存方式 | 室溫 |
| 用法用量 | Parkinson's disease: a\) For early-stage Parkinson disease, the recommended initial dose is 2 mg/24 hr. Depending on clinical response and tolerability, doses may be increased weekly in 2 mg/24 hr increments to a minimum effective dose of 4 mg/24 hr or further to the highest recommended dose of 6 mg/24 hr, as tolerated. b\) For advanced-stage Parkinson disease, the recommended initial dose is 4 mg/24 hours. Depending on clinical response and tolerability, doses may be increased weekly in 2 mg/24 hour increments to the recommended dose of 8 mg/24 hours. c\) Discontinuing Therapy 1\) In patients receiving rotigotine for Parkinson disease, to discontinue therapy, reduce the dose by a maximum of 2 mg/24 hour increments, preferably every other day. |
| 肝功能異常 | 無需調整劑量  Severe hepatic impairment: There are no dosage adjustments provided in manufacturer's labeling \(has not been studied\). |
| 腎功能異常 | 無需調整劑量 |
| 懷孕用藥危分級 | 除非治療上需要 |
| 孕期用藥建議 | N/A |
| 附帶說明 | N/A |
| 哺乳期用藥建議 | Unknown 尚未建立 |
| 附帶說明 | N/A |
| 注射劑給藥建議途徑 | EXT |
| 乾粉稀釋液 | N/A |
| 輸注點滴液 | N/A |
| IVP 用法建議 | N/A |
| IVD 用法建議 | N/A |
| 注意事項 | 每張30cm2貼片含有13.5mg,每24小時釋放6mg主成分。 |

